Zanke B - Search Results

1

Awh CC, Lane AM, Hawken S, Zanke B, Kim IK. Awh CC, et al. Among authors: zanke b. Ophthalmology. 2014 Aug;121(8):e39. doi: 10.1016/j.ophtha.2014.02.029. Epub 2014 May 2. Ophthalmology. 2014. PMID: 24793507 No abstract available.

2

CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration.

Awh CC, Lane AM, Hawken S, Zanke B, Kim IK. Awh CC, et al. Among authors: zanke b. Ophthalmology. 2013 Nov;120(11):2317-23. doi: 10.1016/j.ophtha.2013.07.039. Epub 2013 Aug 21. Ophthalmology. 2013. PMID: 23972322 Clinical Trial.

3

Re: Chew et al.: Genetic testing in persons with age-related macular degeneration and the use of AREDS supplements: to test or not to test? (Ophthalmology 2015;122:212-5).

Awh CC, Zanke B. Awh CC, et al. Among authors: zanke b. Ophthalmology. 2015 Oct;122(10):e62-3. doi: 10.1016/j.ophtha.2015.03.028. Ophthalmology. 2015. PMID: 26398061 No abstract available.

4

Treatment response to antioxidants and zinc based on CFH and ARMS2 genetic risk allele number in the Age-Related Eye Disease Study.

Awh CC, Hawken S, Zanke BW. Awh CC, et al. Ophthalmology. 2015 Jan;122(1):162-9. doi: 10.1016/j.ophtha.2014.07.049. Epub 2014 Sep 4. Ophthalmology. 2015. PMID: 25200399 Clinical Trial.

5

Re: Chew et al.: No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 (Ophthalmology 2014;121:2173-80).

Awh CC, Zanke BW. Awh CC, et al. Ophthalmology. 2015 Aug;122(8):e46. doi: 10.1016/j.ophtha.2014.12.042. Ophthalmology. 2015. PMID: 26210598 No abstract available.

6

Reply: To PMID 25200399.

Awh CC, Zanke BW. Awh CC, et al. Ophthalmology. 2015 Oct;122(10):e59. doi: 10.1016/j.ophtha.2015.02.039. Ophthalmology. 2015. PMID: 26398056 No abstract available.

7

CFH and ARMS2 Polymorphisms Interact with Zinc Supplements in Cognitive Impairment in the Women's Health Initiative Hormone Trial.

Kustra R, Awh CC, Rojas-Fernandez C, Zanke B. Kustra R, et al. Among authors: zanke b. J Alzheimers Dis. 2018;66(2):707-715. doi: 10.3233/JAD-180673. J Alzheimers Dis. 2018. PMID: 30320589

8

CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation.

Vavvas DG, Small KW, Awh CC, Zanke BW, Tibshirani RJ, Kustra R. Vavvas DG, et al. Among authors: zanke bw. Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E696-E704. doi: 10.1073/pnas.1718059115. Epub 2018 Jan 8. Proc Natl Acad Sci U S A. 2018. PMID: 29311295 Free PMC article. Clinical Trial.

9

Reply to Vickers: Pharmacogenetics and progression to neovascular age-related macular degeneration-Evidence supporting practice change.

Vavvas DG, Small KW, Awh C, Zanke BW, Tibshirani RJ, Kustra R. Vavvas DG, et al. Among authors: zanke bw. Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5640-E5641. doi: 10.1073/pnas.1804781115. Epub 2018 Jun 7. Proc Natl Acad Sci U S A. 2018. PMID: 29880713 Free PMC article. No abstract available.

10

A genetic approach to stratification of risk for age-related macular degeneration.

Zanke B, Hawken S, Carter R, Chow D. Zanke B, et al. Can J Ophthalmol. 2010 Feb;45(1):22-7. doi: 10.3129/i09-209. Can J Ophthalmol. 2010. PMID: 20130705 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

99 results

Search Page

Filters